Population | Intervention | Affected AGEs | Affected AGE Receptors and Other Markers | AGE Measure Method | Country (Year) | Reference |
---|---|---|---|---|---|---|
Healthy | CML 2.2 mg/day vs 5.4 mg/day | ↓Serum CML | ↑ Vitamin C | GC–MS/MS | France (2010) | [99] |
Healthy | CML 26 mg/meal vs 75.4 mg/meal | ↓Serum CML |  | ELISA | Germany (2006) | [108] |
Healthy | CML < 5500 kU/day vs > 13,000 kU/day | ↓Serum CML, MG-derivatives | ↓ VCAM-1, 8-isoprostanes, PBMCs, TNF-α, mRNA AGER1 and mRNA RAGE | ELISA | USA (2009) | [91] |
Obese | CML 3302 kU/day vs 14,090 kU/day | ↓Serum CML | ↓ Urine 8-isoprostanes | ELISA | Australia (2011) | [225] |
Diabetic | AGE intake decreased by 50% vs usual diet | ↓Serum CML, MG-derivatives | ↓ PBMCs TNF-α, NF-κB acetylation, and mRNA RAGE; ↑ mRNA AGER1, mRNA SIRT1 and circulating adiponectin | ELISA | USA (2011) | [46] |
Diabetic | CML 3670 kU/day vs 16,300 kU/day | ↓Serum CML | ↓ AGE-modified LDL | ELISA | USA (2004) | [226] |
Diabetic | 7 U CML/mg protein vs 1617 U CML/mg protein | ↓Serum CML |  | ELISA | USA (1997) | [17] |
Diabetic | CML 2750 kU/meal vs 15,100 kU/meal | ↓Serum CML | ↓VCAM-1 | ELISA | Germany (2007–2008) | |
Renal failure | CML 5500 kU/day vs 17,000 kU/day | ↓Serum CML | ↓ AGE-modified LDL, VCAM-1 | ELISA | USA (2003–2004) | |
Chronic kidney disease | CML < 5500 kU/day vs > 13,000 kU/day | ↓Serum CML | ↓ VCAM-1, 8-isoprostanes, TNF-α | ELISA | USA (2009) | [91] |